Radionuclide Therapy [PRRT] for Neuroendocrine Tumours

for neuroendocrine tumours

  • Targeted molecular therapy with Lutetium-DOTATATE for metastatic neuroendocrine group of tumours
  • Mainstay of therapy is improvement in quality of life along with disease control
  • Negligible adverse effects

Did you know ?
Compared to the standard octreotide (used in management of NET), PRRT shows a 79% improvement in progression-free survival